[1]魏 颖,罗 芳.CPAP联合不同时间应用肺表面活性物质对早产呼吸窘迫综合征患儿预后的影响[J].医学信息,2022,35(19):92-95.[doi:10.3969/j.issn.1006-1959.2022.19.025]
　WEI Ying,LUO Fang.Effect of CPAP Combined with Different Time Application of Pulmonary Surfactant on Prognosis of Premature Infants with Respiratory Distress Syndrome[J].Journal of Medical Information,2022,35(19):92-95.[doi:10.3969/j.issn.1006-1959.2022.19.025]
点击复制

CPAP联合不同时间应用肺表面活性物质对早产呼吸窘迫综合征患儿预后的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年19期
页码:
92-95
栏目:
论著
出版日期:
2022-10-01

文章信息/Info

Title:
Effect of CPAP Combined with Different Time Application of Pulmonary Surfactant on Prognosis of Premature Infants with Respiratory Distress Syndrome
文章编号:
1006-1959（2022）19-0092-04
作者:
魏 颖; 罗 芳
（上饶市人民医院儿科，江西 上饶 334000）
Author(s):
WEI Ying; LUO Fang
(Department of Pediatrics,Shangrao People’s Hospital,Shangrao 334000,Jiangxi,China)
关键词:
CPAP; 肺表面活性物质; 呼吸窘迫综合征; 早产儿
Keywords:
CPAP; Pulmonary surfactant; Respiratory distress syndrome; Preterm infants
分类号:
R722.6
DOI:
10.3969/j.issn.1006-1959.2022.19.025
文献标志码:
A
摘要:
目的 观察持续气道正压通气（CPAP）联合不同时间应用肺表面活性物质（PS）对≤32周早产呼吸窘迫综合征（NRDS）患儿预后的影响。方法 选取2020年1月-2021年6月上饶市人民医院收治的≤32周早产NRDS患儿100例，采用随机数字表法分为A组、B组、C组、对照组，各25例。对照组实施经鼻持续气道正压通气（nCPAP）治疗，A组在nCPAP治疗基础上2 h后应用PS，B组在nCPAP治疗基础上2~4 h后应用PS，C组在nCPAP治疗基础上4 h后应用PS；比较各组血气指标、临床疗效、治疗指标及不良反应发生情况。结果 各组血气指标均高于治疗前，且对照组、A组、B组、C组血气指标转好幅度依次升高，差异有统计学意义（P＜0.05）；对照组、A组、B组、C组的治疗总有效率依次升高，差异有统计学意义（P＜0.05）；对照组、A组、B组、C组的nCPAP治疗时间、肺部啰音消失时间、住院时间依次减少，差异有统计学意义（P＜0.05）；对照组、A组、B组、C组的不良反应发生率依次降低，差异有统计学意义（P＜0.05）。结论 nCPAP联合PS治疗早产儿NRDS能够改善患儿预后，且实施nCPAP治疗的时间越长，效果越好。
Abstract:
Objective To observe the effect of CPAP combined with different time application of pulmonary surfactant (PS) on the prognosis of premature infants with respiratory distress syndrome (NRDS)≤32 weeks.Methods A total of 100 premature infants with NRDS≤32 weeks admitted to Shangrao People’s Hospital from January 2020 to June 2021 were selected and divided into group A, group B, group C and control group according to random number table method, with 25 cases in each group. The control group was treated with nCPAP, group A was treated with PS at 2 h after nCPAP treatment, group B was treated with PS at 2-4 h after nCPAP treatment, and group C was treated with PS at 4 h after nCPAP treatment. The blood gas indexes, clinical efficacy, treatment indexes and adverse reactions of each group were compared.Results The blood gas indexes of each group were higher than those before treatment, and the blood gas indexes of the control group, group A, group B and group C increased in turn, the difference was statistically significant (P<0.05). The total effective rate of treatment in the control group, group A, group B and group C increased in turn, and the difference was statistically significant (P<0.05). The nCPAP treatment time, lung rale disappearance time and hospitalization time of the control group, group A, group B and group C decreased in turn, and the difference was statistically significant (P<0.05). The incidence of adverse reactions in control group, group A, group B and group C decreased in turn, the difference was statistically significant (P<0.05).Conclusion nCPAP combined with PS can improve the prognosis of premature infants with NRDS, and the longer the nCPAP treatment, the better the effect.

参考文献/References:

[1]李克伟,娄丹,魏晓霞.早期应用牛肺泡表面活性物质对晚期早产儿及足月儿呼吸窘迫综合征治疗的随机对照研究[J].中国中西医结合儿科学,2015,7(1):52-53.[2]麦隽,綦巧雯,蔡琍璇,等.双水平正压通气和经鼻持续呼吸道正压通气在早产儿呼吸窘迫综合征初始治疗中应用比较[J].中国妇幼保健,2015,30(11):1690-1694.[3]黄丽娜,林玉波.鼻塞式持续气道正压通气在胎龄≥32周早产儿呼吸窘迫综合征的疗效观察[J].吉林医学,2016,37(6):1342-1344.[4]孙波.肺表面活性物质联合机械通气治疗新生儿呼吸窘迫综合征的临床疗效[D].济南:山东大学,2015.[5]张慧杰,温晓红,黄会芝,等.双水平气道正压通气在早产儿轻度呼吸窘迫综合征的应用及对早期肺功能的影响[J].中国儿童保健杂志,2019,27(2):197-201.[6]王晓丽.不同肺表面活性物质治疗早产儿呼吸窘迫综合征的临床研究[J].中国药物与临床,2017,15(5):3-5.[7]余红蕾.经鼻持续气道正压通气对肺表面活性物质治疗新生儿呼吸窘迫综合征效果的影响[J].解放军医药杂志,2017,29(5):75-78.[8]杨松媚,易金远,冯燕妮,等.CPAP联合肺表面活性物治疗新生儿呼吸窘迫综合征的临床疗效及对患者血气指标的影响[J].现代生物医学进展,2020,20(9):1761-1764,1800.[9]黄荔涵.鼻塞持续气道正压通气联合不同时间应用肺表面活性物质对≤32周早产呼吸窘迫综合征患儿预后的影响[J].中国妇幼保健,2018,33(5):1090-1093.[10]林万青,朱晓河,黄国通.早产儿呼吸窘迫综合征使用肺表面活性物质疗效观察[J].深圳中西医结合杂志,2015,25(24):89-90.[11]孙增贤,蓝菊红,张亚丽,等.经静脉留置针注射肺表面活性物质治疗早产儿呼吸窘迫综合征的临床观察[J].中国基层医药,2018,25(1):83-86.[12]王小静,刘玮,张俊杰,等.双水平气道正压通气联合肺泡表面活性物质治疗早产儿呼吸窘迫综合征疗效分析[J].潍坊医学院学报,2019,41(2):93-95.[13]李花,韦红.早晚期实施气管插管-肺表面活性物质-拔管使用持续气道正压通气技术对新生儿呼吸窘迫综合征的影响[J].中国小儿急救医学,2014,21(9):579-581.[14]牛慧敏,徐丽瑾,高洁,等.床旁肺部超声评分对呼吸窘迫患儿持续气道正压通气疗效的评估[J].临床超声医学杂志,2017,19(9):589-592.[15]黄方,刘小辉.肺泡表面活性物质联合双水平正压通气治疗新生儿呼吸窘迫综合征的疗效观察[J].临床肺科杂志,2019,24(6):1023-1025.[16]林报忠,郑通喜,蒋波,等.肺表面活性物质联合双水平气道正压通气治疗新生儿呼吸窘迫综合征的临床疗效[J].实用心脑肺血管病杂志,2017,25(7):77-80.[17]马红茹,吕菊红,李冬梅,等.CPAP联合不同剂量肺表面活性物质对新生儿呼吸窘迫综合征脑氧代谢的影响[J].广西医科大学学报,2019,36(2):285-289.[18]刘亚涛.肺表面活性物质联合BiPAP治疗新生儿呼吸窘迫综合征临床效果观察[J].青岛医药卫生,2018,50(4):285-287.[19]蒋红侠,王彦波,金宝,等.经鼻持续气道正压通气联合丙种球蛋白对新生儿重症肺炎合并心力衰竭的疗效观察[J].河北医药,2019,41(9):1345-1348.[20]朱艳娥.CPAP联合肺表面活性物质对新生儿呼吸窘迫在血气指标及并发症的影响分析[J].医学理论与实践,2020,33(21):3614-3616.[21]李菲,刘小亮.持续正压通气联合肺表面活性物质治疗呼吸窘迫综合征效果及对新生儿安全性临床研究[J].陕西医学杂志,2019,48(1):52-54.[22]张雁云.肺表面活性剂联合CPAP在新生儿呼吸窘迫综合征治疗中的作用分析[J].甘肃科技,2020,36(1):122-124.[23]吴杰斌,翟敬芳,刘枭,等.无创高频与加温湿化高流量鼻导管通气在早产儿呼吸窘迫综合征序贯撤机的临床应用[J].中国小儿急救医学,2021,28(3):165-170.[24]蔡志勇,刘进娣,卞洪亮,等.不同时间应用“气管插管－使用肺表面活性物质－拔管使用持续呼吸道正压通气”技术在呼吸窘迫综合征高危早产儿中的疗效[J].中华实用儿科临床杂志,2016,31(2):101-104.[25]李敏,刘晓琳.足月新生儿呼吸窘迫综合征危险因素分析[J].安徽医学,2016,37(3):330-332．[26]黄娜娜.肺表面活性物质联合鼻塞持续正压通气治疗新生儿呼吸窘迫综合征临床分析[J].哈尔滨医药,2020,40(1):56-57.[27]李艳秋,王丹,李建军.肺泡表面活性物质治疗新生儿呼吸窘迫综合征的临床疗效观察[J].医学综述,2019,25(15):3111-3115.[28]王华,母得志.新生儿呼吸窘迫综合征的通气策略[J].中华妇幼临床医学杂志（电子版）,2017,13(1):10-13.[29]许志有,王耀霜,韩萍,等.肺表面活性物质联合 NCPAP治疗新生儿呼吸窘迫综合征[J].南昌大学学报（医学版）,2015(6):55-57.[30]晏长红,何帆,余曼莉,等.早期CPAP预防胎龄＜30周早产儿呼吸窘迫综合征的临床研究[J].江西医药,2019(5):440-442.

相似文献/References:

[1]郭杨杨,余加林.肺表面活性物质在重症新生儿呼吸窘迫综合征中的应用[J].医学信息,2018,31(09):42.[doi:10.3969/j.issn.1006-1959.2018.09.014]
　GUO Yang-yang,YU Jia-lin.Application of Pulmonary Surfactant in Severe Neonatal Respiratory Distress Syndrome[J].Journal of Medical Information,2018,31(19):42.[doi:10.3969/j.issn.1006-1959.2018.09.014]
[2]孙继飞,张 岚.肺表面活性物质治疗足月新生儿急性呼吸窘迫综合征疗效观察[J].医学信息,2019,32(02):121.[doi:10.3969/j.issn.1006-1959.2019.02.034]
　SUN Ji-fei,ZHANG Lan.Therapeutic Effect of Pulmonary Surfactant on Acute Respiratory Distress Syndrome in Full-term Neonates[J].Journal of Medical Information,2019,32(19):121.[doi:10.3969/j.issn.1006-1959.2019.02.034]
[3]钱元原.肺表面活性物质联合CPAP治疗NRDS的疗效[J].医学信息,2019,32(24):105.[doi:10.3969/j.issn.1006-1959.2019.24.035]
　QIAN Yuan-yuan.Efficacy of Pulmonary Surfactant Combined with CPAP in the Treatment of Neonatal Respiratory Distress Syndrome[J].Journal of Medical Information,2019,32(19):105.[doi:10.3969/j.issn.1006-1959.2019.24.035]
[4]饶 军,程贤高,李晓春,等.布地奈德联合肺表面活性物质气管内注入防治早产儿支气管肺发育不良的效果[J].医学信息,2020,33(23):147.[doi:10.3969/j.issn.1006-1959.2020.23.043]
　RAO Jun,CHENG Xian-gao,LI Xiao-chun,et al.Effect of Intratracheal Injection of Budesonide Combined with Pulmonary Surfactant in the Prevention and Treatment of Bronchopulmonary Dysplasia in Premature Infants[J].Journal of Medical Information,2020,33(19):147.[doi:10.3969/j.issn.1006-1959.2020.23.043]
[5]曾宪铭,黄丽芸,陈 娟,等.肺表面活性物质在新生儿呼吸窘迫综合征接受机械通气治疗中的应用效果及安全性[J].医学信息,2024,37(22):90.[doi:10.3969/j.issn.1006-1959.2024.22.022]
　ZENG Xianming,HUANG Liyun,CHEN Juan,et al.Application Effect and Safety of Pulmonary Surfactant in Mechanical Ventilation Treatment of Neonatal Respiratory Distress Syndrome[J].Journal of Medical Information,2024,37(19):90.[doi:10.3969/j.issn.1006-1959.2024.22.022]

更新日期/Last Update: 1900-01-01